Article Information
History
- March 22, 2023.
Article Versions
- Version 1 (March 1, 2023 - 10:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Kwangsik Nho1,2,3,4,*,
- Shannon L. Risacher1,3,*,
- Liana Apostolova1,3,5,6,
- Paula J. Bice1,3,
- Jared Brosch3,5,
- Rachael Deardorff3,5,
- Kelley Faber6,7,
- Martin R. Farlow3,5,
- Tatiana Foroud3,6,7,
- Sujuan Gao3,8,
- Thea Rosewood1,2,3,
- Jun Pyo Kim1,2,3,
- Kelly Nudelman3,6,7,
- Meichen Yu1,3,
- Paul Aisen9,
- Reisa Sperling10,
- Basavaraj Hooli11,
- Sergey Shcherbinin11,
- Diana Svaldi11,
- Clifford R. Jack12,
- William J. Jagust13,
- Susan Landau13,
- Aparna Vasanthakumar14,
- Jeffrey F. Waring14,
- Vincent Doré15,16,
- Simon M. Laws17,
- Colin L. Masters18,
- Tenielle Porter17,
- Christopher C. Rowe16,
- Victor L Villemagne16,19,
- Logan Dumitrescu20,
- Timothy J. Hohman20,21,
- Julia B. Libby20,
- Elizabeth Mormino22,
- Rachel F. Buckley10,
- Keith Johnson10,23,
- Hyun-Sik Yang10,24,
- Ronald C. Petersen25,
- Vijay K. Ramanan25,
- Prashanthi Vemuri12,
- Ann D. Cohen19,
- Kang-Hsien Fan26,
- M. Ilyas Kamboh26,
- Oscar L. Lopez19,27,
- David A. Bennett28,
- Muhammad Ali29,
- Tammie Benzinger30,
- Carlos Cruchaga29,31,
- Diana Hobbs30,
- Philip L. De Jager32,
- Masashi Fujita32,
- Vaishnavi Jadhav6,33,
- Bruce T. Lamb3,6,33,
- Andy P. Tsai33,34,
- Isabel Castanho35,36,
- Jonathan Mill35,
- Michael W. Weiner37,38,
- Alzheimer’s Disease Neuroimaging Initiative (ADNI)§,
- the Alzheimer’s Disease Neuroimaging Initiative – Department of Defense§,
- the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study)§,
- Australian Imaging, Biomarker & Lifestyle Study (AIBL)§ and
- Andrew J. Saykin1,2,3,4,5,6,¥
- 1Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- 2Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA
- 3Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
- 4Department of BioHealth Informatics, Indiana University-Purdue University, Indianapolis, IN, USA
- 5Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
- 6Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
- 7National Centralized Repository for Alzheimer’s Disease and Related Dementias, Indiana University School of Medicine, Indianapolis, IN, USA
- 8Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA
- 9Department of Neurology, Keck School of Medicine, University of Southern California, San Diego, CA, USA
- 10Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 11Eli Lilly and Company, Indianapolis, IN, USA
- 12Department of Radiology, Mayo Clinic, Rochester, MN, USA
- 13UC Berkeley Helen Wills Neuroscience Institute, University of California - Berkeley, Berkeley, CA, USA
- 14Genomics Research Center, AbbVie, North Chicago, Illinois, USA
- 15CSIRO Health and Biosecurity, Melbourne, Australia
- 16Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia
- 17Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- 18Florey Institute of Neuroscience and Mental Health and The University of Melbourne, Parkville, VIC, Australia
- 19Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 20Vanderbilt Memory & Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN, USA
- 21Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
- 22Department of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA;
- 23Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 24Center for Alzheimer’s Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- 25Department of Neurology, Mayo Clinic, Rochester, MN, USA
- 26Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA
- 27Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 28Department of Neurological Sciences, Rush Medical College, Rush University, Chicago, IL, USA
- 29Department of Psychiatry, Washington University, St. Louis, MO, USA
- 30Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
- 31NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA
- 32Center for Translational and Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA
- 33Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA
- 34Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA
- 35Department for Clinical and Biomedical Sciences, University of Exeter Medical School, University of Exeter, UK
- 36Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA Harvard Medical School, Boston, MA, USA
- 37Departments of Radiology, Medicine, and Psychiatry, University of California-San Francisco, San Francisco, CA, USA
- 38Department of Veterans Affairs Medical Center, San Francisco, CA, USA
- ↵¥Please address correspondence to: Andrew J. Saykin, PsyD Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA Phone: 317-278-6947; Fax. 317-274-1067; E-mail: asaykin{at}iu.edu
↵* These authors contributed equally to this work.
↵§ Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu), the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies (https://ida.loni.usc.edu/collaboration/access/appLicense.jsp;jsessionid=2CC9FA6681E2924181B892706F917FEA) and from the Australian Imaging Biomarkers and Lifestyle (AIBL) Study. As such, the investigators within the ADNI, A4, LEARN, and AIBL consortia contributed to the design and implementation of these studies and/or provided data but, unless named, did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. A complete list of A4 and LEARN investigators can be found at: https://a4study.org/wp-content/uploads/2018/12/A4-Acknowledgements-Journal-Format.pdf. AIBL researchers are listed at www.aibl.csiro.au.
Posted March 22, 2023.
Novel CYP1B1-RMDN2 Alzheimer’s disease locus identified by genome-wide association analysis of cerebral tau deposition on PET
